



9 July 2015

ASX RELEASE

Cleansing Notice – Placement

Anatara Lifesciences Limited (ASX: ANR) (**Anatara**) today issued 5,641,025 fully paid ordinary shares to institutional and sophisticated investors by way of a first tranche placement, at an issue price of \$0.78 per share as outlined in Anatara's announcement of 3 July 2015.

Anatara has issued the shares without disclosure to investors under section 708A(5) *Corporations Act 2001* (Cth) (**Corporations Act**).

Details of the securities issued

Class of securities:	Ordinary shares
ASX Code of the securities:	ANR
Date of the issue or expected issue of the securities:	9 July 2015
Total number of securities issued or expected to be issued:	5,641,025

As required by section 708A(6) of the Corporations Act, Anatara advises:

- (a) the shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, Anatara has complied with:
 - (i) the provisions of chapter 2M of the Corporations Act as they apply to Anatara; and
 - (ii) section 674 of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is 'excluded information' (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act).

An Appendix 3B reflecting the revised capital structure following the issue of the shares under the placement is **attached** to this announcement.

For and on behalf of the board of Anatara.

Mel Bridges
Chairman
Anatara Lifesciences Limited

For personal use only





ANATARA
LIFESCIENCES

For more information please contact:

General inquiries

Mel Bridges
Chairman
+61 (0) 413 051 600
melbridges@parmacorp.com

Media inquiries

Gavin Lower
Buchan Consulting
+61 3 8866 1215
glower@buchanwe.com.au

About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

For personal use only

